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Abstract
Vaccination represents a viable and attractive strategy for therapeutic treatment of cancers
by the power of a patient’s own immune system. Major advances in cellular and molecu-
lar immunology have led to the approval of the first therapeutic cancer vaccine by FDA.
However, the development of cancer vaccines remains infant. Maximizing the therapeutic
efficacy while minimizing side effects of the therapeutic cancer vaccine remains key
challenges to this field. In this review, we summarized the recently developed strategies
to induce anti-tumor responses in vivo to improve the outcomes of cancer vaccines, with
an emphasis on the guiding principles that are critical for rational design of effective and
safe vaccines against cancers.
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1. Introduction
Recent understanding in cancer immunology and the development of cancer immunotherapy
have remarkably advanced the clinical treatment of cancer, leading to US Food and Drug
Administration approvals of cell-based immunotherapies (Provenge, Kymriah, and Yescarta),
and immune checkpoint inhibitors (Ipilimumab, Nivolumab, Atezolizumab, Avelumab),
among others. Regardless of the progress, in most immunotherapies for cancer patients, the
response is often of low frequency and moderate avidity, and does not result in objective
clinical responses [1, 2]. For example, while immune checkpoint blockade therapies of various
cancers yield impressive clinical outcomes, these therapies do not alter the frequency of tumor-
specific T cells. Additionally, although dendritic cells (DCs) pulsed with tumor associated
antigens can result in the expansion of antigen-specific T cells, the level of responses is often
too low to mediate long-lasting tumor destruction [3]. This situation can be remedied with
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therapeutic cancer vaccines which are designed to induce or augment the magnitude and
quality of antitumor immune responses.
Currently many diverse therapeutic vaccine strategies are under development or being evalu-
ated in clinical trials. Based on their content, they may be classified into different categories,
including cell-based vaccines, subunit vaccines, and genetic vaccines. Each of these vaccine
platforms targets specific immune pathways and has strengths and weaknesses detailed in our
next discussion. One of the major goals for these vaccine strategies is to break the tumor-
related immunosuppression. This challenge can be partially addressed by the development of
new vaccine strategies, or optimization of current vaccines including the choice of antigen, the
immunological adjuvants, formulations for delivery, vaccine efficacy, safety and toxicity con-
siderations. Additionally, preclinical studies have clearly demonstrated that vaccines alone
might not be sufficiently potent to overcome the complex immunosuppression within the
tumor microenvironment [4]. Therefore, vaccines in combination with other immunotherapies
might provide synergistic mechanisms to amplify the therapeutic outcomes. For example, the
preclinical success of vaccines combined with immune checkpoint blockade have highlighted
the potential to move beyond current paradigms of cancer vaccines [5, 6]. Here we summarize
recent strategies to improve therapeutic vaccines for cancer.
2. Immunological background
The immune system is comprised of a network of lymphoid organs, tissues and different types
of cells including lymphocytes, dendritic cells and nature killer cells. The immune system
plays a crucial role in protecting the body against microbial pathogens and also in restraining
the development of cancer [7–9]. Engineering the immune system to provide protective immu-
nological memory (a procedure called vaccination) has been one of the most successful and
cost effective medical interventions to date, saving millions of lives every year via pediatric
and adult immunizations [9]. The process that immune system responds to foreign pathogens,
allergies, self-damaged cells, and graft is called an immune response, which can be generally
classified into innate response and adaptive response.
Innate response or nonspecific immune response, recognizes invading pathogens via PAMPs
(pathogen associated molecular patterns) that are evolutionarily conserved molecular motifs
expressed by a variety of microbes [10, 11]. PAMPs are mainly detected and recognized by
innate immune cells through Toll-like receptors (TLRs) and other pattern recognition receptors
(PRRs) [10]. Recognition of PAMPs by immune cells including phagocytic cells (macrophages
and neutrophil) and antigen presenting cells (APCs) triggers a cascade of signaling pathways
and activates these immune cells, promoting phagocytosis of pathogens and providing the
first line of defense against many common pathogens. Innate response causes rapid inflamma-
tion at the site of infection which results in redness, swelling, heat, and pain. Innate response
also plays a crucial role in the initiation of adaptive immune responses [10, 11].
Adaptive response, on the other hand, is referred to as a specific immune response. During
adaptive response, highly specialized lymphocytes including T cells and B cells are activated
by APCs engulfing and processing pathogens or antigenic molecules associated with pathogens.
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Once activated, these lymphocytes undergo proliferation and differentiation into effector cells
which can eliminate pathogens or inhibit their proliferation and growth. In addition to speci-
ficity, another feature that differentiates adaptive response from innate response is immuno-
logical memory which is developed after initial adaptive response to a specific pathogen and
can recall specific immune response to the same pathogen in future encounters. Adaptive
immune responses are tightly linked to innate immune responses [12]. For example, the TLR
stimulus promote maturation of dendritic cells (DCs), the most efficient APCs and trigger the
upregulation of costimulatory molecules on DCs for efficient antigen presentation.
Although it appears that adaptive response is more advanced and sophisticated than innate
one, their roles in immunomodulation are inseparable and they complement each other in
eliciting effective immune response to pathogens. Innate response is generally prerequisite to
the activation of adaptive response which in return can enhance innate immunity by effector
molecules such as cytokines and antibodies [10–12].
Cancer is one of the leading causes of death worldwide, accounting for more than 8 million
death each year [13]. While traditionally cancer is treated with surgery, radiation, or chemo-
therapy, immunotherapy which harnesses the power of patients’ own immune system has
come of age over the last decades as a new treatment modality to fight against cancer, with
cancer vaccine emerging as a novel approach to cancer treatment [14–18]. Unlike the tradi-
tional vaccine by which antibody responses are needed to prevent the disease from develop-
ing, therapeutic cancer vaccines heavily rely on cytotoxic T cell responses that are designed for
patients with established diseases [14]. The initiation and maintenance of anti-tumor immune
responses is a multi-step, complex process that involves the coordinated action of immune
cells and molecular signals within the immune system [14]. For example, the induction of
systemic antitumor immunity involves the priming of both CD4+ and CD8+ T cells specific for
tumor-associated antigens. The process is initiated with antigen uptake by professional APCs
especially DCs. In the presence of appropriate immune signals (e.g., TLR ligands), DCs are
activated and migrate to LNs, where they present antigen fragments in the context of major
histocompatibility complex (MHC) to effector T cells. In the draining LNs, CD4+ and CD8+ T
cells recognize peptides presented via MHC class II and MHC class I on DC surface, respec-
tively. And if DCs are properly activated, these T-cells proliferate and differentiate into effector
cells that can directly kill cancer cells (CD8+ “killer” T-cells) or secrete cytokines that help other
cells (CD4+ “helper” T-cells) [19–21]. Effector T cells traffic to tumor site, recognize tumor cells
by T cell receptor (TCR), and secrete cytotoxins such as perforin and granzymes which trigger
tumor cell apoptosis. An effective cancer vaccine aims to target these essential steps and
reinforce tumor-specific T cells immunity to combat tumors. Adaptive immunity-dominated
anti-tumor activities are illustrated in Figure 1.
Most vaccines in use today were developed by techniques that were pioneered more than
100 years ago and do not provide protection in many diseases. For example, although highly
effective for combating acute infections such as polio, measles and diphtheria, traditional
vaccination technologies have failed to elicit immune responses that provide protection against
chronic infections (e.g. HIV, malaria) and have not succeeded in therapeutic settings, which are
designed to harness the patient’s immune system to treat an existing disease (e.g. HIV or
cancer). Traditional vaccine approaches induced transient anti-tumor immunity that failed to
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control tumor growth, primarily due to tolerance mechanisms induced by tumor cells [22]. To
shield themselves from immune attack, tumor cells are able to evade the immune detection,
recognition and subsequent immune attack through a variety of mechanisms [23]. First, most
tumor antigens recognized by cytotoxic CD8+ T cells are encoded from “self”. Self-antigens
expressed by solid tumors are intrinsically nonimmunogenic and do not efficiently stimulate
naïve T cells. As a disease of mutations, the genetic instability or changes in cancer cells may
potentially promote the generation of tumor antigen variants that are theoretically recognized
as “non-self” by the immune system [24]. Thus, cancer vaccines that introduce neoantigens or
tumor cell variants are promising in the induction of effective anti-tumor immune responses.
Second, survived tumor cells have acquired the ability to resist immune recognition by
expressing low level or defective MHC molecules, leading to insufficient antigen presentation
[23]. Third, the upregulation of immune checkpoint ligand programmed death-ligand 1 (PD-
L1) on tumor cells also leads to inactivation of effector T cells [23]. Accordingly, inhibitors of
immune checkpoints, which target the PD-L1/PD-1 pathways, might reinforce the potency of
immune response induced by cancer vaccines. In addition, tumor cells can produce suppres-
sive cytokines including VEGF (vascular endothelial growth factor), TGF-β (transforming
growth factor-β) and IL-10 (interleukin-10) to develop an immunosuppressive microenviron-
ment, which further inhibits the activation and functions of tumor-specific effector cells [23].
These suppressive cytokines in turn recruit regulatory immune cells, especially regulatory T
cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [23]. Typically, Tregs and MDSCs
function as major effectors of immunosuppression to inhibit host-protective anti-tumor
Figure 1. Immune activation of tumor-specific CTLs and the mechanisms of action of CTLs killing tumor cells. APCs
acquire tumor antigen, migrate to the draining LNs, and present antigen to T cells in the context of peptide/MHC
complex. Activated CTLs traffic to tumor site, trigger the programmed death of tumor cells through the perforin-
granzymes pathway or FasL-Fas/TNF-TNFR death receptor pathway.
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immune response by secreting suppressive cytokines IL-10 and TGF- β, and by expressing
high level of co-inhibitory molecules cytotoxic T-lymphocytes-associated protein 4 (CTLA-4)
and PD-1 [23]. Administration of molecular adjuvants such as TLR agonists, which promote
the production of proinflammatory cytokines, could be an attractive approach to neutralize the
impact of suppressive cytokines modulated by tumor cells. Finally, to escape immune destruc-
tion, tumor cells cunningly overexpress anti-apoptotic proteins, such as B-cell lymphoma 2
(Bcl-2), which regulate cell death and protect themselves from immune response-induced
apoptosis [25]. In parallel, FasL expressed on tumor cells binds to Fas on CTLs and directly
causes the apoptosis of CTLs [26]. Collectively, as demonstrated in Figure 2, a combination of
these underlying mechanisms ultimately contribute to the immune escape of tumor cells,
which have posed challenging and complicated hurdles for the development of cancer vac-
cines. To improve the therapeutic efficacy of cancer vaccines and break the tolerance in tumors,
the orchestration of therapeutic strategies that induce long-lasting antitumor immunity and
overcome immune escape is the key for a successful treatment.
3. Cell-based cancer vaccines
Dendritic cells (DCs) are professional APCs that play a pivotal role in the regulation of cell-
mediated immunity, and thus are key targets in cancer vaccine design [16–18]. The promising
results from clinical trials recently have led to the approval of the first DC-based therapeutic
Figure 2. Mechanisms associated with immune escape of tumor cells. Fundamental Ag (antigen) modification leads to
compromised immunogenicity of tumor cells (1); downregulation of MHC molecules on tumor cells also reduces the
chance of tumor antigen presentation (2); abnormal expression of co-stimulatory molecules CD80, CD86 and PD-L1 leads
to the inactivation or anergy of effector T cells (3); suppressive cytokines e.g., TGF-βand IL-10 produced by tumor cells
inhibit the proliferation of effector CTLs and NK cells (4) but stimulate regulatory cells (Treg) and MDSC to expand,
creating an immunosuppressive microenvironment (5); intracellular overexpression of anti-apoptotic molecules Bcl-2
prevents tumor cells from immune response-induced apoptosis (6); FasL expressed on tumor cells in turn induces the
programmed death of CTLs through death receptor pathway (7).
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cancer vaccine by FDA [3]. There are generally two approaches to target DCs: in situ delivery
of antigens via ligands that are specific for endocytic receptors expressed at the surface of DCs
and ex-vivo generated antigen-loaded DCs. Though the latter approach requires laborious and
expensive manipulation, immunotherapy based on ex-vivo tumor antigen loaded DCs
bypasses the intrinsic dysfunctions of endogenous DCs in cancer patients, enabling the effi-
cient priming of both CD4 and CD8 T cells. One of most successful examples of ex vivo DC-
based vaccines is the use of sipuleucel-T for treating metastatic prostate cancer [27]. The FDA-
approved sipuleucel-T cellular immunotherapy is comprised of autologous peripheral blood
mononuclear cells (PBMCs) that are ex vivo pulsed with prostatic acid phosphatase (PAP) and
activated with granulocyte-macrophage colony stimulating factor (GM-CSF). With sipuleucel-
T treatment, the risk of death of patients was reduced by 22% in contrast with that of patients
who received the placebo treatment. As a result, overall survival among male patients with
metastatic castration-resistant prostate cancer was prolonged via the administration of
sipuleucel-T therapy [27]. Despite the fact that DC-based vaccines can induce T cell responses,
objective clinical responses are low and DC-based vaccinations have not met their expectation
as an effective modality in treating other cancers [3]. Several factors might be limiting the
efficacy of current DC vaccines: the types and sources of DC, the route of injection, and the
migration to LNs. It has been estimated that less than 5% of the injected DCs reach the LNs
[28], the anatomic sites where the immune responses are orchestrated. To overcome the insuf-
ficient migration of DCs, intranodal (IN) administration of DCs has been explored. In several
clinical studies [29, 30], IN administration of mature DCs appeared to be safe, and resulted in
superior T-cell sensitization.
Another challenge associated with DC vaccine is the insufficient antigen-presentation by DCs.
Recent research suggests that high affinity [31, 32] and prolonged peptide–MHC presentation
[33–35] of targeted epitopes are required for effective tumor eradication and tumor stroma
destruction by specific T cells, presumably through the persistent T cell stimulation. However,
DC pulsed with tumor associated peptides exhibits low T cell affinity and short half-lives of
peptide–MHC complexes due to the clonal deletion of high affinity T cells and dissociation of
peptide from MHC, respectively. In the later scenario, peptide degradation and rapid MHC
turnover, leading to weak and transient T cell stimulation [36]. In addition, matured DCs loss
their ability for antigen uptake and processing. This has posed a major barrier to the develop-
ment of effective DC-based vaccines in clinic. Attempt to improve and stabilize MHC epitopes
on DC surface has encompassed the use of altered peptide ligands (APLs) [37, 38], which
incorporates mutated amino-acids in MHC anchor residues, and genetic modifications, which
reprogram dendritic cells to express tumor antigens [39, 40].
Whole tumor cell vaccine is another cell-based vaccination approach currently in preclinical
development and clinical trials. In this approach, tumor cells are modified to prevent replica-
tion and administered to patients to induce antitumor immune responses. The efficacy of
whole-tumor cells vaccine has been investigated for more than 20 years [41]. One of the key
advantages of using whole tumor cells as vaccine is that the cells provide a source of all
potential antigens including neoantigens, eliminating the need for antigen identification.
GVAX, by which tumor cells are genetically modified to overexpress granulocyte macrophage
colony stimulating factor (GM-CSF), irradiated and adoptively transferred back to the patient,
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is an early example of tumor cell vaccine. A meta-analysis about 1800 patients revealed that
patients treated with whole tumor vaccines showed a more robust objective response—8.1%
than those immunized with formulated tumor antigens—3.6% [42]. Prostate GVAX vaccine is
an excellent example of whole tumor vaccines. In a clinical trial, administration of Prostate
GVAX vaccines in patients with metastatic HRPC (hormone-refractory prostate cancer)
exhibited improved survival of most patients, compared with the treatment of taxane chemo-
therapy alone [43–45]. Despite the promise, whole tumor cell vaccination typically requires
substantial ex vivo genetic modification, leading to high cost, long processes, and stability,
reproducibility and regulatory concerns. Additionally, immunization with whole-tumor cells
has not resulted in significant long-term benefits in both preclinical models and in clinical
trials. To address these issues, recently, injectable tumor cell-loaded cryogel sponges which
deliver antigen-carrying tumor cells along with GM-CSF and TLR agonist was developed [46].
This biomaterials-based vaccination eliminates genetic modification, yet still delivers key DC
activating factors. Immunization with cryogels in mice elicited local infiltration of DCs, which
subsequently induced potent, durable T-cell responses in a melanoma model.
Apart from manipulating DCs and tumor cells to activate effector T cells, T cell-based immu-
notherapy provides a straightforward method to augment tumor-specific T cell immunity. One
outstanding example of this therapy is adoptive T cell therapy, which involves the ex vivo
manipulation and proliferation of antigen-specific T cells. Using this technique, two CAR
(chimeric antigen receptors) T cell therapies have recently been approved by FDA. The
approved therapies are targeted CD19, which is a common marker of lymphoma cells, to treat
relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic
leukemia (ALL), respectively [47]. The CAR T cell therapy features the structural modification
on autologous T cells to target virtually any tumor antigens. In general, T cells are engineered
with the CAR structure which consists of a target element, scFv (single-chain variable frag-
ments), and co-stimulatory domain and essential activation signaling domain (Figure 3). In the
most recent approved CAR T therapy, patients with relapsed and refractory ALL were infused
with autologous T cells transduced with a CD19-directed CAR, and 90% of them succeeded in
complete remission [48]. Although adoptive T cell therapy has achieved remarkable efficacy in
leukemia, it is less successful when this therapy is applied to solid tumor partially due to
immunosuppression and rapid dysfunction of transferred effector T cells. To overcome these
obstacles, a recent study demonstrated T cell surface coupling of nanoparticles loaded with IL-
15 and IL-21 which fuel the T cells and boost the cell-based therapy [49]. Further study from
the same group demonstrated that targeting TGF-β inhibitors to adoptive T cells via
immunoliposomes greatly enhanced tumor-specific T cell immunity and significant B16F10
tumor regression in comparison to free adoptive T cells. This study suggested a complemen-
tary factor to maximize the efficacy of adoptive T cell therapy in cancer treatment [50].
Although cell-based therapy is a promising and effective strategy for cancer treatment, there
are still several drawbacks related to this type of therapy. For example, ex vivomanipulation on
DCs or T cells is labor intensive and expensive, plus the safety concerns about CARs in clinical
trials [51]. A promising strategy to simultaneously overcome the cost and safety limitation is to
create effective CAR T cells in vivo without T cell isolation. Recently, nanoparticles carrying
genetic materials was delivered to T cells in mice. This approach avoided the tedious and
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expensive ex vivo T cell manipulation [52]. More research may be needed to demonstrate the
efficacy and safety of this new in situ approach in humans in the future.
4. In situ vaccines
As some cancer therapies may fail in most patients with solid tumors, in situ vaccination can
provide another prospect of driving a systemic anti-tumor immunity. In situ vaccination exploits
local intratumoral treatment to simultaneously destruct tumor tissue and provides the immune
system with an antigen source for the induction of antitumor immunity [53, 54]. Unlike tradi-
tional vaccines where selected tumor-associated antigens are used, in situ vaccination exploits
complete tumor-related antigenic repertoire, including tumor-specific neoantigens derived from
non-synonymous mutations [55]. Further, in situ vaccines can set the stage for potent antitumor
immunity by inducing inflammation and facilitating the recruitment and activation of immune
cells to the tumor. Thus, in situ vaccine approach provides opportunities for broad, more effective
and less toxic treatment strategies to promote systemic antitumor immunity. This approach also
bypasses the difficulties of isolating and preparing individualized vaccine ex vivo, providing a
personalized treatment for cancer patients.
A variety of intratumoral treatments (e.g., radiation, cryotherapy) have been delivered directly to
the tumors to induce tumor cell death, release tumor antigens while providing pro-inflammatory
signals, which result in systemic activation of anti-tumor T cell responses, followed by inflam-
matory infiltration of T lymphocytes into the tumor [55–59]. While these early studies demon-
strate the potential of in situ tumor destruction in promoting both T cell and humoral responses,
the efficacy and wide-spread adoption of in situ vaccination have been limited. The major
challenge lies in the relatively weak antitumor immunity following primary tumor destruction.
For example, radiofrequency ablation or cryotherapy allows in situ tumor destruction and
releases large amount of tumor antigens, but only induce a weak and transient immune response
Figure 3. The general idea of CAR T cell therapy. T cells are isolated from patients’ blood and subsequently engineered
with a special CAR; genetically modified T cells are then expanded ex vivo and adoptively transferred back to patients.
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which fails to prevent tumor relapse [57]. Preclinical and clinical studies combining tumor
ablation with local administration of CpG-containing oligonucleotides (single-stranded oligonu-
cleotides containing unmethylated cytosine-guanine motifs that bind TLR-9and serve as potent
molecular adjuvants) can boost the induction of systemic antitumor effects [57]. Recent results of
clinical trials and pre-clinical models demonstrated that intralesional treatment with cytokines,
small drugs of immune checkpoint and radiation led to systemic anti-tumor immunity with
limited toxicity [60, 61]. In Phase I/II clinical trial in non-Hodgkin’s lymphoma, treatment of
intratumoral injection of CpG and low-dose radiation safely induced objective responses at
distal non-treated sites in nearly 30% of patients [62]. However, rapid dissemination of
unformulated CpG from injection site often leads to systemic toxicity [63]. Conversely,
immobilizing CpG ODNs or other immunostimulants [64, 65] in synthetic scaffolds at the tumor
site blocks the systemic toxicity.
Overall, in situ vaccination represents an alternative and attractive approach to tackle the
issues related with neoantigens due to gene mutations in tumor cells. By harnessing the power
of nanotechnology as well as molecular adjuvants, it is possible to induce effective immune
responses while at the same time overcoming the local immunosuppression at the tumor sites.
5. Nanoparticle-based vaccines
Nanoparticles have emerged as the platform of choice to improve the efficacy and safety of
subunit vaccines. Nanoparticles have long served as versatile carriers and been extensively
used for the delivery of therapeutic agents, including drugs, antigens, adjuvants, cytokines
and other immune modulators. Nanomaterials are known interact with immune cells and
carry vaccines to LNs through the interstitial flow, which exists in the lymphatic circulation
with velocities of 0.1–1 μm/s [66–68]. This is because nanoparticles are able to mimic the
sizes, shape, charge and surface features of virus particles, facilitating the entrance to the
lymphatic capillary. Hubbell and Swartz showed that 25 nm diameters polypropylene sul-
fide (PPS) nanoparticles were transported and captured by APCs in the LN more efficiently
than the same nanoparticles with 100 nm diameters [68]. Inorganic nanoparticles such as
gold nanoparticles (AuNPs) have also successfully been shown in an animal model for
localization of the sentinel LNs following intradermal injection [69–72], and have extensively
used as improved vaccine carriers. Additionally, nanoparticles are ideal co-delivery platform
in that multiple components can be conjugated or encapsulated in a single particle, fulfilling
the requirement of co-delivery of antigens and activation signals in vaccines. We have
developed a silica nanoparticle-based delivery platform (SiNPs) which targets tumor antigen
and TLR-9 agonist to APCs in the LNs following subcutaneous injection [73]. Vaccine loaded
SiNPs led to dramatically enhanced induction of antigen-specific B and T cell responses as
compared to soluble vaccines, which in turn drove a protective antitumoral immunity in a
murine tumor model [73]. Additionally, SiNPs vaccines greatly reduced the production of
systemic proinflammatory cytokines and completely abrogated splenomegaly, key systemic
toxicities of TLR-9 agonist that limit its advances in clinical applications. Our results
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demonstrate structure-optimized silica nanocarriers can be used as an effective and safe
platform for targeted delivery of subunit vaccines [73].
Liposome represents a versatile and convenient approach for vaccine delivery [74]. However, its
application is limited by the in physical stability in vivo. To improve liposome stability,
interbilayer-crosslinked multilamellar vesicles (ICMVs) was recently developed. These physi-
cally crosslinked vesicles were relatively stable but rapidly release their vaccine cargos when
internalized by DCs. Results from this nanoparticle-based vaccine in mice showed striking
enhancement on cellular and humoral responses, characterized by 30% antigen-specific CD8+ T
cell expansion and nearly 1000 times increase in antigen-specific antibody titer compared with
unformulated vaccine [75]. Nanoparticles can also be used to deliver a full set of tumor associ-
ated antigens to DCs to induce anti-tumor immunity. A novel study assessed the therapeutic
efficacy of PLGA (poly(lactic-co-glycolic acid)) nanoparticles (100 nm) coated with tumor cell
membranes [76]. Membrane-coated PLGA nanoparticles were decorated with a TLR 4 agonist
monophosphoryl lipid A (MPLA) which readily activated DCs to license the proliferation and
differentiation of CD8+ T cells in a melanoma model. This artificial biomimetic nanoparticle
formulation proposed a unique targeting approach that could be utilized for cancer immuno-
therapy. But it remains to be determined whether tumor membrane-coated nanoparticles can
simultaneously elicit broad T cell immune responses against various tumor associated antigens.
Another approach of using nanoparticles for cancer vaccines is artificial antigen presenting cells
(aAPCs) [77]. aAPCs, functioning as direct activating units for T cells expansion, are emerging as
a prominent and desirable strategy to reverse immunosuppression microenvironment in tumors
and activate highly avid tumor-specific T cells. Nanoparticles-based aAPCs are a new approach
to efficiently present tumor antigen while at the same time avoid the tolerogenic mechanisms
associated with traditional antigen presenting cells. Nanoparticle aAPCs typically have a nano-
particle core coated with peptide/MHC and T cell stimulatory signals. Nanomaterials have been
used include polymer (e.g., PLGA), inorganic particles (e.g., iron-oxide), and biomaterials (e.g.,
liposomes). Immune checkpoint inhibitors have also been conjugated on particle surfaces. The
administration of artificial APCs coated with HLA-peptide tetrameric complexes and anti-CD28
mAb together boosted the specific activation of antigen-specific CD4+ T cells [78]. In vivo, adop-
tive transfer of aAPCs obviously restrained tumor growth of a melanoma model in mice, along
with IL-2 treatment [79]. While the therapeutic efficacy of these aAPCs needs more evaluation
and trials, they certainly boost the development and advancement of cancer vaccine design.
Generally, nanoparticle-based vaccines hold great promise and tremendous potential in the
treatment of cancers, and therapeutic efficacy generated by nanoparticle-based approach greatly
promotes the development of next-generation cancer vaccines. Although some nanoparticles are
commercially available and effective in cancer immunotherapy, it is still critical to physically and
chemically orchestrate the design of nanoparticle-based vaccines on a structural basis. By opti-
mizing the rationale of vaccine design and the routes of administration, we may conquer the
underlying challenges associated with nanoparticles, which may include potential cytotoxicity to
tissues and unexpected accumulation in local sites.
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6. Molecular vaccines
The use of nanoparticles for vaccines application has also raised safety concerns. Nanoparticles
are typically encapsulated or conjugated with vaccines and their surface are modified with
immune cell targeting ligands. However, it remains difficult to design nanocarriers which
meet all the criteria for vaccine targeting. Most current nanoparticles do not reach a clinic
application primarily due to requirements for complex designs including surface engineering
to reduce host immune response, hydrophobic modification to enhance drug encapsulation,
and incorporation of ligands to maintain immune cells targeting [80, 81]. Possible stability and
toxicological issues including immunogenicity also greatly restrict the nanocarrier’s clinical
application in the short-term [80, 81]. We recently devised an ‘albumin-hitchhiking’ molecular
approach which uniquely delivers vaccines to APCs in the LNs by binding to and transporting
with endogenous albumin [63, 82]. In this approach, molecular vaccines are conjugated to a
structure-optimized lipophilic albumin-binding tail linked by a solubility-promoting polar
polymer and follow subcutaneous injection, bind tightly to albumin protein. Albumin binding
increases the hydrodynamic size of molecular adjuvants, prevents them from rapidly flushing
into the bloodstream and re-targets them to lymphatics and draining LNs, where they are
filtered by APCs and accumulate. Meanwhile, because most vaccine components are trapped
in the LNs, ‘albumin-hitchhiking’ vaccine also greatly enhances the safety profile by reducing
systemic dissemination. We show that a long diacyl lipid (≥16 carbons) and a long polyethyl-
ene glycol (≥36 EG units) favors the albumin binding and LN accumulation in vivo [63, 82].
Subsequent immunizationwith the structure-optimized ‘albumin-hitchhiking’ vaccines exhibited
massive antigen-specific T cells priming and improved anti-tumor efficacy. Administration of
low dose of albumin-binding TLR-9 agonist and peptide antigens resulted in dramatically
increased antigen-specific CD8+ T-cell expansion relative to unmodified vaccine, as demonstrated
by dramatic increases in the frequency of antigen-specific T cells measured in the peripheral.
Importantly, efficient LN targeting achieved by albumin-binding vaccines also greatly reduces
acute systemic side effects of TLR-9 agonist which had made it less attractive as a prophylactic
vaccine adjuvant.
Although amphiphilic vaccines are prominent and excellent candidates in treating tumor-
bearing mice, more study and work are required to translate this approach to clinical trials in
human cancer models to validate the therapeutic and safety benefits. Additionally, the poten-
tial toxicity to LNs may be considered and addressed, and finding lipid-modified adjuvants
that can function in human immune system is also urgently needed.
Another molecular vaccine which has emerged as an alternative cancer immunotherapy regi-
men is the DNA vaccine. DNA vaccination holds great potential in clinical translation because
of their simplicity, safety and low cost [83]. In DNA vaccines, genetically engineered DNA
encoding immunogenic antigens and immunostimulatory factors are injected into the host,
and subsequently traffic into the cells for in vivo expression of therapeutic agents by using the
hosts’ protein expression machineries. In this way, DNA vaccines represent an innovative
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strategy to induce specific anti-tumor immune response and circumvent immune escape. The
injected DNA partially functions as an immunological adjuvant to stimulate the innate immune
system due to its bacterial origin [84]. On the other hand, the antigens, expressed by plasmid-
transfected host cells, can be processed and subsequently presented by MHC molecules which
are critical to license the activation of antigen-specific CD8+ T cells. One of the studies revealed
that DNA vaccine encoding alphavirus replicon activated the innate immunity and induced
cellular responses against self-tumor associated antigen tyrosinase related protein 1, showing
impressive efficacy in reversing immunosuppression in tumor [85]. Another innovative work
that elaborated the design of DNA vaccine also showed remarkable effectiveness in overcoming
immune escape in tumor models [86]. In this study, the plasmid DNA was engineered to encode
a secreted chimeric protein consisting of a single-chain trimer (SCT) of MHC I heavy chain, β2-
microglobulin, and peptide antigen linked to IgG. The chimeric protein derived from this plas-
mid DNA was able to form a dimer which bound avidly to antigen-specific CD8+ T cells and
elicited T cell stimulation and expansion directly, bypassing antigen presenting cells. This design
simplified the process of antigen presentation and potentially avoided suboptimal activation
associated with traditional antigen presentation. Additionally, the IgG domain in this construct
enabled chimeric proteins to target the Fc receptor on APCs which initiated the subsequent
cascade of immune activation in LNs. Based on this creative design, intradermal administration
of this DNA vaccine induced potent Trp2-specific CD8+ T cell dominant immune responses and
showed enhanced therapeutic efficacy in B16 melanoma tumor model in mice [86]. DNA vac-
cines have also been tested in clinical trials to evaluate their efficacy in human cancer, melanoma
[87], breast cancer [88], prostate cancer [89], and cervical cancer [90].
DNA vaccination provides an innovative and attractive platform for cancer immunotherapy
with additional advantages like low cost, well-defined safety. Technically, DNA vaccines can
be readily customized and engineered, which makes large-scale production possible. In addi-
tion, DNA vaccines are widely recognized as safe therapeutics in both animal and human
clinical trials [89, 91, 92]. Despite a variety of advantages of DNA vaccines, the intrinsic poor
immunogenicity have made DNA vaccine less successful in generating desirable therapeutic
efficacy in most cancers. Therefore, future development of DNA vaccines may need to focus on
their rationale design to greatly improve the immune potency of DNA vaccines in cancers.
7. Combined immunotherapy
Although monotherapy of most cancer vaccines can achieve therapeutic efficacy in cancer
treatment to varying extent, therapeutic benefits may be further improved if these cancer
vaccines can be administrated in a combinational way to complement each other against
cancer. Theoretically, when effector T cells are activated, co-inhibitory molecules CTLA-4 and
PD-1 can also be expressed and up-regulated on T cell due to the suppressive microenviron-
ment of tumors, which may compromise the efficacy of vaccine-based cancer therapy. To
minimize the impact of the expression of co-inhibitory molecules, a combinational therapy of
cancer vaccines and immune checkpoints inhibitors may achieve a cure to cancer treatment.
The idea has been realized and supported by several preclinical studies [93, 94]. The first study
revealed that breast cancer derived immunogenic multi-peptide vaccine plus anti-PD-1
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antibody functioned as a combinational therapy approach and thus prolonged the vaccine-
induced progression-free survival period in breast tumor-bearing mice, along with augmented
expansion of Tc1 and Tc2 CD8 T cells [93]. Another study demonstrated that anti-PD-1 anti-
body and GVAX synergistically enhanced the anti-tumor immune responses with great thera-
peutic efficacy in established melanoma tumor-bearing mice. In contrast with monotherapy of
vaccine or PD-1 inhibitors, only a simultaneous administration of both therapies achieved
repeated expansion of antigen-specific CD8+ T cells [94]. Similar strategy using GVAX and
anti-CTLA-4 antibody has also been utilized for treating metastatic pancreatic cancer, giving
rise to objective response in 20% of tumor-bearing patients who have been resistant to chemo-
therapy [95]. Cancer vaccine-based immunotherapy may weaken the resistance of some can-
cers to immune checkpoint inhibitors, whereas immune checkpoint inhibitors may make up
the drawbacks for cancer vaccines by decreasing the possibility of immune escape in tumors
and thus enhancing the efficacy of vaccination. Other combination, such as vaccines plus
adoptive T cell transfer might synergistically amplify the antitumor immunity, as demon-
strated in recent studies. In summary, the combinational therapy is emerging as a more
powerful and comprehensive strategy to address the immune escape associated with tumors
and fuel the tumor-antigen specific T cell immune responses. But more studies are needed to
test the clinical efficacy of this combinational therapy and assess the potential issues related to
it, such as systemic toxicity and anti-drug antibody response.
8. Conclusion and future perspective
Immunotherapies have demonstrated their potential to generate robust antitumor responses
and are continuing to grow as a new treatment modality for cancers when administrated alone
or as an addition for other “physical” or “chemical” therapies. Strategies based on immuno-
therapy mainly focus on the induction of potent immune response, especially effector T cell
response, against tumor antigens and variants due to genetic mutations, and the decrease or
blockade of intrinsic immunosuppression in tumors. The immune system is a sophisticated
and complicated entity, which may require elaborate design and engineering of therapeutic
agents to reverse tumor-induced immune imbalance. As previously discussed, each single
immunotherapy may not be perfect for cancer treatment. The future work may continue
improving the rational design of cancer vaccines to maximize their efficacy while minimizing
side effects. To date, several immunotherapies have been approved by FDA and dozens more
are under clinical evaluation. Indeed, we are at the dawn of a whole new era for cancer
treatments. With the rapid technological advancement in the field, cancer vaccines, in combi-
nation with traditional cancer treatment, may ultimately lead to a miracle cure for the vast
majority of cancer patients.
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